Abstract
The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nature Reviews. Nephrology |
Vol/bind | 14 |
Udgave nummer | 11 |
Sider (fra-til) | 659-660 |
ISSN | 1759-5061 |
DOI |
|
Status | Udgivet - 2018 |